Developer docs
API playgroundTry for free, no card

Search company profiles

Vernalis

Full company profile

uuid000a2nx

Namestring
Vernalis
Legal namestring
Vernalis (R&D) Limited
Websiteurl
vernalis.com
Company typeenum
Private
Founded yearint
1997
Descriptiontext

Vernalis (R&D) Limited is a UK-based, revenue-generating contract research organization providing integrated drug discovery services to pharmaceutical and biotechnology companies. Operating from a single site at Granta Park, Cambridge, the company employs approximately 70 scientists organized across protein science, hit identification and assay, biophysics and structural biology, medicinal and computational chemistry, cell biology, and DMPK functions. Its core technical platform centers on fragment-based drug discovery (FBDD) and structure-based drug discovery (SBDD), augmented by DNA Encoded Library (DEL) capabilities (including proprietary PAC-FragmentDEL technology developed with parent company HitGen), proprietary Off-Rate Screening (ORS), in-house X-ray crystallography (over 7000 structures solved across 70+ targets), NMR (Bruker 600 MHz with QCI-F cryoprobe), and SPR (Biacore 8K and T200) platforms. The company operates a project-based fee-for-service commercial model, offering collaboration structures that range from long-term multi-target programs to short discrete pieces of work, with named enterprise clients including Servier, Genentech, Lundbeck, Pierre Fabre, and C4X Discovery.

Vernalis generates revenue exclusively through these custom contract research agreements; pricing is not publicly disclosed. Its go-to-market is direct enterprise engagement supplemented by scientific conference presence, peer-reviewed publications, and open-source software contributions (notably the Vernalis KNIME Nodes, one of the most downloaded KNIME community extensions in 2023). The company was originally founded as RiboTargets (pre-1998) and operates today as a wholly owned subsidiary of HitGen Inc., a Shanghai-listed (688222.SH) DEL technology company, gaining access to parent company DEL infrastructure while maintaining operational independence with its own leadership team in Cambridge. Recent strategic activity includes a drug discovery collaboration with C4X Discovery in inflammatory disease (April 2024) and entry into the €60M+ LIGAND-AI consortium led by Pfizer and the Structural Genomics Consortium (January 2026), positioning the company within the emerging AI-driven drug discovery ecosystem as a wet-lab data generation partner.

Short descriptiontext

Vernalis is a UK-based contract research organization that provides integrated fragment-based and structure-based drug discovery services to pharmaceutical and biotechnology clients from its Cambridge laboratories, operating as a wholly owned subsidiary of HitGen Inc.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery services, fragment-based drug discovery, structure-based drug discovery, medicinal chemistry services, preclinical drug development
Industry3 codes
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Drug Discovery Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Discovery Contract Research Services
TypeProfessional Services
Description

Vernalis generates revenue through fee-for-service drug discovery collaborations with pharmaceutical and biotechnology companies. Collaboration structures range from long-term multi-target projects to short discrete pieces of work. Services span the full drug discovery value chain from protein production through to pre-clinical candidate nomination.

2Collaborative Research Agreements
TypeProfessional Services
Description

Collaborative partnerships where work is funded by partners (e.g., C4X Discovery collaboration in inflammatory disease). Vernalis receives research funding while partners retain ownership of resulting intellectual property and have options to extend collaborations.

Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Vernalis provides integrated, fee-for-service drug discovery collaborations to pharmaceutical and biotechnology companies, spanning the full value chain from protein production and hit identification (using fragment-based drug discovery, DNA-encoded library screening, and proprietary PAC-FragmentDEL) through structure-based lead optimisation, medicinal and flow chemistry, cell biology, and DMPK to pre-clinical candidate nomination. Services are delivered either as long-term multi-target programs or as short discrete pieces of work from its Cambridge, UK laboratories.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Over 7000 crystal structures determined across more than 70 protein targets
+5 more records
Product overview1 text field

Vernalis is a drug discovery services company offering an integrated platform of research services spanning from protein science through to candidate selection. The core offering consists of Protein Science Services (expression and purification), Hit ID and Assay services (including proprietary PAC-FragmentDEL Technology), Biophysics and Structural Biology, Chemistry Services (with Flow Chemistry and KNIME Nodes as key sub-products), Cell Biology, and DMPK services. These services are offered as a unified drug discovery platform enabling programs from gene to candidate, with collaboration structures varying from long-term multi-target projects to discrete pieces of work. Vernalis is a wholly owned subsidiary of HitGen Inc. and operates from Cambridge, UK.

Product and service9 records
1Protein Science Services
CategoryDrug Discovery Services / Protein Production
Description

Protein expression and purification services using multiple expression systems (E. coli, yeast, insect, mammalian cells) with ÄKTA chromatography systems. Includes protein quality control, site-specific labelling, and production of crystallographic-grade protein for structural studies. Supports Vernalis's internal and partner drug discovery programmes.

2Hit ID and Assay Services
CategoryDrug Discovery Services / Hit Identification
Description

Hit identification services combining fragment-based drug discovery (FBDD), DNA Encoded Library (DEL) technology, medium-throughput biochemical screening (MTS), virtual screening, and knowledge-based approaches. Includes proprietary fragment libraries and PAC-FragmentDEL technology for partners seeking validated hit series.

3Biophysics and Structural Biology Services
CategoryDrug Discovery Services / Structural Biology
Description

Biophysical and structural biology services including X-ray crystallography (in-house Bruker D8 source plus synchrotron access), NMR (Bruker 600 MHz with QCI-F cryoprobe), SPR (Biacore 8K and T200), ITC (Auto-iTC200), ASMS, and thermal shift assay. Has determined over 7,000 crystal structures for more than 70 protein targets.

4Chemistry Services
CategoryDrug Discovery Services / Medicinal Chemistry
Description

Medicinal, synthetic, analytical, and computational chemistry services covering kinases, PPIs, GPCRs, and ion channels. Includes PROTAC and ADC design, flow chemistry, photochemistry, electrochemistry, and KNIME-based cheminformatics. Delivers lead optimisation and pre-clinical candidates for partners.

5Cell Biology Services
CategoryDrug Discovery Services / Cell Biology
Description

Cell-based screening and pharmacology services including high-content imaging, flow cytometry, cell-based reporter assays (BiBiT), ELISA, high-throughput western blot, in-cell target engagement, RNAseq, and cytotoxicity. Includes a Class 2 containment laboratory for anti-infectives testing.

6DMPK Services
CategoryDrug Discovery Services / DMPK-ADME
Description

In vitro ADME assays (kinetic solubility, PAMPA, Caco-2, MDCK, CYP inhibition, microsomal clearance, UGT clearance, hepatocyte clearance, metabolite identification), ex vivo bioanalysis, in vivo study design and management, bioanalysis of plasma and biofluids, tissue preparation, PK/PD evaluation, and pharmacokinetic reporting for partner programmes.

7PAC-FragmentDEL Technology
CategoryDrug Discovery Services / Hit Identification Technology
Description

Proprietary photoactivated capture fragment DNA-encoded library technology developed in collaboration with HitGen. Each library member consists of a fragment linked to a photoactivatable diazirine group; photoactivation covalently attaches binding fragments to the protein and hits are identified by PCR and Next-Generation Sequencing. Overcomes limitations of conventional fragment screening by requiring only small amounts of protein, running rapidly at low concentrations, and solubilising fragments via the DNA tag. Offered to partners as a differentiated hit identification capability.

8Flow Chemistry Services
CategoryDrug Discovery Services / Synthetic Chemistry
Description

Flow chemistry services built around one of the largest Syrris Asia flow chemistry systems in the world. Supports automated synthesis, preparation of large compound libraries in 96-well plate format, crude reaction mixture screening by SPR, organometallic chemistry, photochemistry, electrochemistry, and 3D-printed custom labware including back-pressure regulators. Delivers scalable, reproducible synthetic chemistry for partner programmes.

9Vernalis KNIME Nodes (Open Source)
CategoryScientific Software / Open-Source Cheminformatics
Description

Open-source KNIME community contribution providing workflow nodes for cheminformatics, structural informatics, data access, and general utility tasks. Includes PDB Connector, fingerprint manipulation, SMILES processing via Speedy SMILES nodes, Matched Molecular Pair Analysis (MMPA), and molecular property calculations. Released as a Trusted KNIME Community contribution; usable by the broader drug discovery community.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-01-20
Description

Vernalis joined the LIGAND-AI consortium, a multi-sector public-private partnership funded by the Innovative Health Initiative (IHI) with a budget exceeding €60 million. The five-year initiative brings together 18 partners across nine countries to generate large open datasets of protein-ligand interactions and train AI models capable of predicting molecular binding for thousands of human proteins. Led by Pfizer and the Structural Genomics Consortium (SGC), the project targets rare, neurological, and oncological conditions. All data will be shared according to FAIR principles.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-20
Description

SGC is the project coordinator and co-leader of the LIGAND-AI consortium alongside Pfizer. SGC leads the open science ecosystem and coordinates data sharing according to FAIR principles across the 18 consortium partners.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-20
Description

Pfizer co-leads the LIGAND-AI consortium alongside the Structural Genomics Consortium as a major pharmaceutical partner contributing to AI-driven drug discovery through open science.

Strategic tierCoreTypeOthersAnnounced on2026-01-20
Description

Vernalis (R&D) Limited is a wholly owned subsidiary of HitGen Inc. (688222.SH). Vernalis is a member of the HitGen group of companies, which provides access to DNA Encoded Library (DEL) technology including PAC-FragmentDEL, OpenDEL, and DEL screening capabilities. HitGen is listed on the Shanghai Stock Exchange.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-20
Description

Partner in the LIGAND-AI consortium. Abcam contributes recombinant protein engineering and production capabilities to generate high-quality binding datasets to support predictive model development.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-20
Description

Partner in the LIGAND-AI consortium, contributing to the public-private partnership for AI-driven drug discovery through open science.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-20
Description

Partner in the LIGAND-AI consortium, contributing to the public-private partnership for AI-driven drug discovery through open science.

8C4X Discovery
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-08
Description

Vernalis (R&D) Limited, a wholly owned subsidiary of HitGen Inc., entered a collaboration with C4X Discovery to identify modulators of an undisclosed high-value target involved in inflammatory disease. Vernalis uses its protein science and Hit ID platforms to produce the target protein and identify and characterise small molecule ligands. The research at Vernalis is funded by C4XD, with C4XD retaining ownership of resulting IP and having an option to extend the collaboration.

vernalis.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing collaboration partner in drug discovery programs, including work on Bcl-2 family proteins for cancer and DYRK1A kinase inhibitors. Vernalis and Servier have collaborated across multiple projects with integrated project teams.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Present and past collaborator on challenging therapeutic targets as part of Vernalis's broad partnering network.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Present and past collaborator on challenging therapeutic targets as part of Vernalis's broad partnering network.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Present and past collaborator on challenging therapeutic targets as part of Vernalis's broad partnering network.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based CRO offering integrated drug discovery services from hit identification through pre-clinical candidates, with strength in medicinal chemistry, DMPK and in vitro pharmacology. Direct competitor for pharma outsourced discovery work, particularly on challenging targets.

TypeBroad incumbent
Description

Large global CRO offering end-to-end drug discovery and development services across multiple modalities and therapeutic areas. Competes for multi-target discovery collaborations with the same pharma clients as Vernalis, with broader scale but less specialisation in FBDD.

TypeBroad incumbent
Description

Global CRO with extensive discovery, safety assessment and manufacturing services. Overlaps with Vernalis on early discovery and DMPK and competes for integrated discovery programs with large pharma, though most scale sits in later-stage and safety services.

TypeBroad incumbent
Description

China-headquartered CRO with integrated discovery, DMPK and manufacturing capabilities. Competes for outsourced discovery work globally, including structure-based and fragment-based approaches, often at lower price points.

TypeEmerging player
Description

Parent company of Vernalis, listed on the Shanghai Stock Exchange, focused on DNA Encoded Library (DEL) technology including OpenDEL and PAC-FragmentDEL. Sister-company relationship creates both synergy and potential channel conflict for Vernalis's UK-based fragment and SBDD services.

TypeEmerging player
Description

Computational drug discovery platform combining physics-based modelling with collaborative discovery services. Competes for early-stage discovery budgets from pharma, increasingly on AI-enabled hit identification that overlaps with Vernalis's structural biology work.

TypeEmerging player
Description

AI-native drug discovery company offering end-to-end discovery partnerships with pharma. Represents a new entrant competing for the same pharma discovery spend, particularly as AI-driven design becomes more credible.

TypeBroad incumbent
Description

Large China-based CRO/CDMO with extensive discovery, preclinical and manufacturing services. Competes globally for outsourced discovery work, including with China-based biotech clients, with materially larger scale than Vernalis.

9C4X Discovery
TypeEmerging player
Description

UK-based drug discovery company using its Conformetrix and other proprietary chemistry platforms. A current Vernalis partner (April 2024 inflammatory disease collaboration), illustrating the biotech client segment Vernalis serves; also a potential competitor for discovery work with biotech.

TypeBroad incumbent
Description

Global CRO providing drug discovery, in vitro pharmacology and ADME services through the former Eurofins Pharma Discovery and acquired capabilities. Overlaps with Vernalis on assay development, biophysics and DMPK contracts from pharma and biotech.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vernalis

Contract Drug Discovery Servicesvernalis.com

Vernalis is a UK-based contract research organization that provides integrated fragment-based and structure-based drug discovery services to pharmaceutical and biotechnology clients from its Cambridge laboratories, operating as a wholly owned subsidiary of HitGen Inc.

What Vernalis does

Vernalis (R&D) Limited is a UK-based, revenue-generating contract research organization providing integrated drug discovery services to pharmaceutical and biotechnology companies. Operating from a single site at Granta Park, Cambridge, the company employs approximately 70 scientists organized across protein science, hit identification and assay, biophysics and structural biology, medicinal and computational chemistry, cell biology, and DMPK functions. Its core technical platform centers on fragment-based drug discovery (FBDD) and structure-based drug discovery (SBDD), augmented by DNA Encoded Library (DEL) capabilities (including proprietary PAC-FragmentDEL technology developed with parent company HitGen), proprietary Off-Rate Screening (ORS), in-house X-ray crystallography (over 7000 structures solved across 70+ targets), NMR (Bruker 600 MHz with QCI-F cryoprobe), and SPR (Biacore 8K and T200) platforms. The company operates a project-based fee-for-service commercial model, offering collaboration structures that range from long-term multi-target programs to short discrete pieces of work, with named enterprise clients including Servier, Genentech, Lundbeck, Pierre Fabre, and C4X Discovery.

Vernalis generates revenue exclusively through these custom contract research agreements; pricing is not publicly disclosed. Its go-to-market is direct enterprise engagement supplemented by scientific conference presence, peer-reviewed publications, and open-source software contributions (notably the Vernalis KNIME Nodes, one of the most downloaded KNIME community extensions in 2023). The company was originally founded as RiboTargets (pre-1998) and operates today as a wholly owned subsidiary of HitGen Inc., a Shanghai-listed (688222.SH) DEL technology company, gaining access to parent company DEL infrastructure while maintaining operational independence with its own leadership team in Cambridge. Recent strategic activity includes a drug discovery collaboration with C4X Discovery in inflammatory disease (April 2024) and entry into the €60M+ LIGAND-AI consortium led by Pfizer and the Structural Genomics Consortium (January 2026), positioning the company within the emerging AI-driven drug discovery ecosystem as a wet-lab data generation partner.

Vernalis firmographics

Firmographics
Name
Vernalis
Legal name
Vernalis (R&D) Limited
Website
https://vernalis.com
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
251–500 employees
Short description
Vernalis is a UK-based contract research organization that provides integrated fragment-based and structure-based drug discovery services to pharmaceutical and biotechnology clients from its Cambridge laboratories, operating as a wholly owned subsidiary of HitGen Inc.
Ownership category
akta.pro rank

Vernalis industry classification

Industry
Product category
Contract Drug Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Drug discovery services
  • Fragment-based drug discovery
  • Structure-based drug discovery
  • Medicinal chemistry services
  • Preclinical drug development

Where Vernalis is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Vernalis business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Drug Discovery Contract Research Services: Vernalis generates revenue through fee-for-service drug discovery collaborations with pharmaceutical and biotechnology companies. Collaboration structures range from long-term multi-target projects to short discrete pieces of work. Services span the full drug discovery value chain from protein production through to pre-clinical candidate nomination.
  2. Collaborative Research Agreements: Collaborative partnerships where work is funded by partners (e.g., C4X Discovery collaboration in inflammatory disease). Vernalis receives research funding while partners retain ownership of resulting intellectual property and have options to extend collaborations.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Vernalis product offering

Product offering

Core offering

Vernalis provides integrated, fee-for-service drug discovery collaborations to pharmaceutical and biotechnology companies, spanning the full value chain from protein production and hit identification (using fragment-based drug discovery, DNA-encoded library screening, and proprietary PAC-FragmentDEL) through structure-based lead optimisation, medicinal and flow chemistry, cell biology, and DMPK to pre-clinical candidate nomination. Services are delivered either as long-term multi-target programs or as short discrete pieces of work from its Cambridge, UK laboratories.

Product overview

Vernalis is a drug discovery services company offering an integrated platform of research services spanning from protein science through to candidate selection. The core offering consists of Protein Science Services (expression and purification), Hit ID and Assay services (including proprietary PAC-FragmentDEL Technology), Biophysics and Structural Biology, Chemistry Services (with Flow Chemistry and KNIME Nodes as key sub-products), Cell Biology, and DMPK services. These services are offered as a unified drug discovery platform enabling programs from gene to candidate, with collaboration structures varying from long-term multi-target projects to discrete pieces of work. Vernalis is a wholly owned subsidiary of HitGen Inc. and operates from Cambridge, UK.

Differentiator

Problem solved

Functional benefit

Products and services

  • Protein Science Services Protein expression and purification services using multiple expression systems (E. coli, yeast, insect, mammalian cells) with ÄKTA chromatography systems. Includes protein quality control, site-specific labelling, and production of crystallographic-grade protein for structural studies. Supports Vernalis's internal and partner drug discovery programmes.
  • Hit ID and Assay Services Hit identification services combining fragment-based drug discovery (FBDD), DNA Encoded Library (DEL) technology, medium-throughput biochemical screening (MTS), virtual screening, and knowledge-based approaches. Includes proprietary fragment libraries and PAC-FragmentDEL technology for partners seeking validated hit series.
  • Biophysics and Structural Biology Services Biophysical and structural biology services including X-ray crystallography (in-house Bruker D8 source plus synchrotron access), NMR (Bruker 600 MHz with QCI-F cryoprobe), SPR (Biacore 8K and T200), ITC (Auto-iTC200), ASMS, and thermal shift assay. Has determined over 7,000 crystal structures for more than 70 protein targets.
  • Chemistry Services Medicinal, synthetic, analytical, and computational chemistry services covering kinases, PPIs, GPCRs, and ion channels. Includes PROTAC and ADC design, flow chemistry, photochemistry, electrochemistry, and KNIME-based cheminformatics. Delivers lead optimisation and pre-clinical candidates for partners.
  • Cell Biology Services Cell-based screening and pharmacology services including high-content imaging, flow cytometry, cell-based reporter assays (BiBiT), ELISA, high-throughput western blot, in-cell target engagement, RNAseq, and cytotoxicity. Includes a Class 2 containment laboratory for anti-infectives testing.
  • DMPK Services In vitro ADME assays (kinetic solubility, PAMPA, Caco-2, MDCK, CYP inhibition, microsomal clearance, UGT clearance, hepatocyte clearance, metabolite identification), ex vivo bioanalysis, in vivo study design and management, bioanalysis of plasma and biofluids, tissue preparation, PK/PD evaluation, and pharmacokinetic reporting for partner programmes.
  • PAC-FragmentDEL Technology Proprietary photoactivated capture fragment DNA-encoded library technology developed in collaboration with HitGen. Each library member consists of a fragment linked to a photoactivatable diazirine group; photoactivation covalently attaches binding fragments to the protein and hits are identified by PCR and Next-Generation Sequencing. Overcomes limitations of conventional fragment screening by requiring only small amounts of protein, running rapidly at low concentrations, and solubilising fragments via the DNA tag. Offered to partners as a differentiated hit identification capability.
  • Flow Chemistry Services Flow chemistry services built around one of the largest Syrris Asia flow chemistry systems in the world. Supports automated synthesis, preparation of large compound libraries in 96-well plate format, crude reaction mixture screening by SPR, organometallic chemistry, photochemistry, electrochemistry, and 3D-printed custom labware including back-pressure regulators. Delivers scalable, reproducible synthetic chemistry for partner programmes.
  • Vernalis KNIME Nodes (Open Source) Open-source KNIME community contribution providing workflow nodes for cheminformatics, structural informatics, data access, and general utility tasks. Includes PDB Connector, fingerprint manipulation, SMILES processing via Speedy SMILES nodes, Matched Molecular Pair Analysis (MMPA), and molecular property calculations. Released as a Trusted KNIME Community contribution; usable by the broader drug discovery community.

Quantifiable outcome

  • Over 7000 crystal structures determined across more than 70 protein targets
  • +5 more outcomes

Companies that use Vernalis

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Vernalis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability5 records

Feature9 records

Vernalis partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered flagship, core and minor.

  • LIGAND-AI Consortium (IHI Project)flagshipStrategic or Co-development Partner · 20 January 2026Vernalis joined the LIGAND-AI consortium, a multi-sector public-private partnership funded by the Innovative Health Initiative (IHI) with a budget exceeding €60 million. The five-year initiative brings together 18 partners across nine countries to generate large open datasets of protein-ligand interactions and train AI models capable of predicting molecular binding for thousands of human proteins. Led by Pfizer and the Structural Genomics Consortium (SGC), the project targets rare, neurological, and oncological conditions. All data will be shared according to FAIR principles.
  • Structural Genomics Consortium (SGC)coreStrategic or Co-development Partner · 20 January 2026SGC is the project coordinator and co-leader of the LIGAND-AI consortium alongside Pfizer. SGC leads the open science ecosystem and coordinates data sharing according to FAIR principles across the 18 consortium partners.
  • PfizercoreStrategic or Co-development Partner · 20 January 2026Pfizer co-leads the LIGAND-AI consortium alongside the Structural Genomics Consortium as a major pharmaceutical partner contributing to AI-driven drug discovery through open science.
  • HitGen Inc.coreOthers · 20 January 2026Vernalis (R&D) Limited is a wholly owned subsidiary of HitGen Inc. (688222.SH). Vernalis is a member of the HitGen group of companies, which provides access to DNA Encoded Library (DEL) technology including PAC-FragmentDEL, OpenDEL, and DEL screening capabilities. HitGen is listed on the Shanghai Stock Exchange.
  • Abcam LimitedminorStrategic or Co-development Partner · 20 January 2026Partner in the LIGAND-AI consortium. Abcam contributes recombinant protein engineering and production capabilities to generate high-quality binding datasets to support predictive model development.
  • AstraZeneca UK LimitedminorStrategic or Co-development Partner · 20 January 2026Partner in the LIGAND-AI consortium, contributing to the public-private partnership for AI-driven drug discovery through open science.
  • Novo NordiskminorStrategic or Co-development Partner · 20 January 2026Partner in the LIGAND-AI consortium, contributing to the public-private partnership for AI-driven drug discovery through open science.
  • C4X DiscoverycoreStrategic or Co-development Partner · 8 April 2024Vernalis (R&D) Limited, a wholly owned subsidiary of HitGen Inc., entered a collaboration with C4X Discovery to identify modulators of an undisclosed high-value target involved in inflammatory disease. Vernalis uses its protein science and Hit ID platforms to produce the target protein and identify and characterise small molecule ligands. The research at Vernalis is funded by C4XD, with C4XD retaining ownership of resulting IP and having an option to extend the collaboration.
  • ServiercoreStrategic or Co-development PartnerLong-standing collaboration partner in drug discovery programs, including work on Bcl-2 family proteins for cancer and DYRK1A kinase inhibitors. Vernalis and Servier have collaborated across multiple projects with integrated project teams.
  • GenentechminorStrategic or Co-development PartnerPresent and past collaborator on challenging therapeutic targets as part of Vernalis's broad partnering network.
  • LundbeckminorStrategic or Co-development PartnerPresent and past collaborator on challenging therapeutic targets as part of Vernalis's broad partnering network.
  • Pierre FabreminorStrategic or Co-development PartnerPresent and past collaborator on challenging therapeutic targets as part of Vernalis's broad partnering network.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Vernalis competitors and assessment

Company assessment

Direct peers

  • Sygnature Discovery: UK-based CRO offering integrated drug discovery services from hit identification through pre-clinical candidates, with strength in medicinal chemistry, DMPK and in vitro pharmacology. Direct competitor for pharma outsourced discovery work, particularly on challenging targets.

Broad incumbents

  • Evotec: Large global CRO offering end-to-end drug discovery and development services across multiple modalities and therapeutic areas. Competes for multi-target discovery collaborations with the same pharma clients as Vernalis, with broader scale but less specialisation in FBDD.
  • Charles River Laboratories: Global CRO with extensive discovery, safety assessment and manufacturing services. Overlaps with Vernalis on early discovery and DMPK and competes for integrated discovery programs with large pharma, though most scale sits in later-stage and safety services.
  • Pharmaron: China-headquartered CRO with integrated discovery, DMPK and manufacturing capabilities. Competes for outsourced discovery work globally, including structure-based and fragment-based approaches, often at lower price points.
  • WuXi AppTec: Large China-based CRO/CDMO with extensive discovery, preclinical and manufacturing services. Competes globally for outsourced discovery work, including with China-based biotech clients, with materially larger scale than Vernalis.
  • Eurofins Discovery: Global CRO providing drug discovery, in vitro pharmacology and ADME services through the former Eurofins Pharma Discovery and acquired capabilities. Overlaps with Vernalis on assay development, biophysics and DMPK contracts from pharma and biotech.

Emerging players

  • HitGen: Parent company of Vernalis, listed on the Shanghai Stock Exchange, focused on DNA Encoded Library (DEL) technology including OpenDEL and PAC-FragmentDEL. Sister-company relationship creates both synergy and potential channel conflict for Vernalis's UK-based fragment and SBDD services.
  • Schrödinger: Computational drug discovery platform combining physics-based modelling with collaborative discovery services. Competes for early-stage discovery budgets from pharma, increasingly on AI-enabled hit identification that overlaps with Vernalis's structural biology work.
  • Exscientia: AI-native drug discovery company offering end-to-end discovery partnerships with pharma. Represents a new entrant competing for the same pharma discovery spend, particularly as AI-driven design becomes more credible.
  • C4X Discovery: UK-based drug discovery company using its Conformetrix and other proprietary chemistry platforms. A current Vernalis partner (April 2024 inflammatory disease collaboration), illustrating the biotech client segment Vernalis serves; also a potential competitor for discovery work with biotech.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Vernalis social profiles

Digital presence

Vernalis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vernalis leadership team

Management profile

Number of profiles

Profiles14 records

Vernalis funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vernalis M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vernalis

What does Vernalis do?

Vernalis provides integrated, fee-for-service drug discovery collaborations to pharmaceutical and biotechnology companies, spanning the full value chain from protein production and hit identification (using fragment-based drug discovery, DNA-encoded library screening, and proprietary PAC-FragmentDEL) through structure-based lead optimisation, medicinal and flow chemistry, cell biology, and DMPK to pre-clinical candidate nomination. Services are delivered either as long-term multi-target programs or as short discrete pieces of work from its Cambridge, UK laboratories.

Is Vernalis a public or private company?

Vernalis is a private company. It is classified as corporate owned and is currently operating.

When was Vernalis founded?

Vernalis was founded in 1997. It employs 251 to 500 people.

Where is Vernalis based?

Vernalis is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Vernalis make money?

Two revenue lines are on record. Drug Discovery Contract Research Services are the primary driver. The others are collaborative Research Agreements.

Who are Vernalis's main competitors?

Sygnature Discovery is listed as a direct peer. Broad incumbents are Evotec, Charles River Laboratories, Pharmaron, WuXi AppTec and Eurofins Discovery. Emerging players are HitGen, Schrödinger, Exscientia and C4X Discovery.

Does Vernalis have an API?

No public API is recorded for Vernalis.

What industry is Vernalis in?

Vernalis's product category is Contract Drug Discovery Services. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswirePierre Fabre Laboratories y Vernalis anuncian colaboraciónPierre Fabre Laboratories and Vernalis announced a long-term partnership to identify preclinical candidates against multiple oncology targets. Under the agreement, Vernalis will leverage fragment-based and structure-based methods to identify small molecules, with research funded by Pierre Fabre, which will also handle clinical milestones and receive royalties on marketed products. The collaboration combines Vernalis' drug discovery expertise with Pierre Fabre's oncology experience to identify drug candidates for treating various types of cancer for further development and commercialization.PR NewswireLes Laboratoires Pierre Fabre et Vernalis annoncent une collaboration pour la recherche et le développement de médicaments en oncologieLes Laboratoires Pierre Fabre et Vernalis (R&D) Ltd, filiale à 100 % de HitGen Inc., ont annoncé un partenariat à long terme pour identifier des candidats pré-cliniques ciblant plusieurs indicateurs oncologiques. Vernalis utilisera des méthodes basées sur les fragments et la structure pour identifier des petites molécules, tandis que Pierre Fabre financera la recherche et versera des paiements d'étapes ainsi que des redevances sur les produits commercialisés. Cette collaboration combine l'expertise de Vernalis en découverte de médicaments avec l'expérience en oncologie de Pierre Fabre pour développer de nouveaux traitements contre le cancer.PR NewswireVernalis Research, a fully owned subsidiary of HitGen Inc., and Unison Medicines Inc. announce a research collaboration in the field of anti-infectivesVernalis Research and Unison Medicines announced a research collaboration on an undisclosed bacterial target, with Vernalis designing small molecules. Unison will finance all activities, and Vernalis will receive downstream milestones and royalties. Vernalis also invested in Unison's first financing round.PR NewswireImpact of the Coronavirus on Cough & Cold Medications - GlaxoSmithKline, Vernalis, Pfizer, Taro Pharmaceuticals and Bayer Seeing Increased Demand for Their OTC ProductsPharmaceutical companies including GlaxoSmithKline, Vernalis, Pfizer, Taro Pharmaceuticals, and Bayer are experiencing increased demand for their over-the-counter cough, cold, flu, and pain relief products during the COVID-19 pandemic. Consumers with mild COVID-19 symptoms are stocking up on these medications as health authorities recommend self-isolation at home rather than visiting healthcare facilities. ResearchAndMarkets.com published this market analysis examining how the outbreak has driven demand shifts in the OTC medication sector.GlobeNewswireShore Capital Stockbrokers Limited : Form 8.5 (EPT/RI) - Vernalis plcShore Capital Stockbrokers Ltd disclosed dealings in Vernalis plc shares on 1 October 2018, buying and selling 814 ordinary shares at 6.14p each. The disclosure is made under Rule 8.5 of the Takeover Code.GlobeNewswireShore Capital Stockbrokers Limited : Form 8.5 (EPT/RI) - Vernalis PlcShore Capital Stockbrokers Ltd disclosed dealings in Vernalis Plc shares on 16 August 2018, purchasing and selling 25,914 ordinary shares at 6.16p and 6.02p respectively. The disclosure was made under Rule 8.5 of the Takeover Code.GlobeNewswireShore Capital Stockbrokers Limited : Form 8.5 (EPT/RI) - Vernalis PlcShore Capital Stockbrokers Ltd disclosed dealings in Vernalis Plc ordinary shares on 14 August 2018, purchasing 3,898 shares at 6.06p and selling 18,898 shares at the same price. The disclosure was made under Rule 8.5 of the Takeover Code.GlobeNewswireShore Capital Stockbrokers Limited : Form 8.5 (EPT/RI) - Vernalis PlcShore Capital Stockbrokers Ltd disclosed dealings in Vernalis Plc ordinary shares on 13 August 2018, purchasing 147,881 shares at 6.06p and selling 132,881 shares at 6.06p. The disclosure was made under Rule 8.5 of the Takeover Code.GlobeNewswireShore Capital Stockbrokers Limited : Form 8.5 (EPT/RI) - Vernalis PlcShore Capital Stockbrokers Ltd disclosed a public dealing in Vernalis Plc shares on 10 August 2018, buying and selling 250,288 ordinary shares at 6p each. The disclosure was made under Rule 8.5 of the Takeover Code, with no other dealings or agreements noted.GlobeNewswireShore Capital Stockbrokers Limited : Form 8.5 (EPT/RI) - Vernalis PlcShore Capital Stockbrokers Ltd disclosed a public dealing in Vernalis Plc shares on 09 August 2018, buying and selling 893,330 ordinary shares at 6p each. The disclosure was made under Rule 8.5 of the Takeover Code, with no other dealings or agreements noted.